Early vasopressor administration in pediatric blunt liver and spleen injury: An ATOMAC+ study.

Autor: Notrica DM; Phoenix Children's Hospital. Electronic address: dnotrica@phoenixchildrens.com., Sussman BL; Phoenix Children's Hospital., Sayrs LW; Phoenix Children's Hospital., St Peter SD; Children's Mercy Kansas City., Maxson RT; Arkansas Children's Hospital., Alder AC; Children's Medical Center part of Children's Health(SM)., Eubanks JW 3rd; Le Bonheur Children's Hospital., Johnson JJ; The Children's Hospital at OU Medical Center., Ostlie DJ; Phoenix Children's Hospital; American Family Children's Hospital., Ponsky T; Akron Children's Hospital., Naiditch JA; Dell Children's Medical Center., Leys CM; American Family Children's Hospital., Lawson KA; Dell Children's Medical Center., Greenwell C; Children's Medical Center part of Children's Health(SM)., Bhatia A; Children's Healthcare of Atlanta., Garcia NM; Dell Children's Medical Center.
Jazyk: angličtina
Zdroj: Journal of pediatric surgery [J Pediatr Surg] 2021 Mar; Vol. 56 (3), pp. 500-505. Date of Electronic Publication: 2020 Jul 12.
DOI: 10.1016/j.jpedsurg.2020.07.007
Abstrakt: Background: No prior studies have examined the outcomes of early vasopressor use in children sustaining blunt liver or spleen injury (BLSI).
Methods: A planned secondary analysis of vasopressor use from a 10-center, prospective study of 1004 children with BLSI. Inverse probability of treatment weighting (IPTW) was used to compare patients given vasopressors <48 h after injury to controls based on pretreatment factors. A logistic regression was utilized to assess survival associated with vasopressor initiation factors on mortality and nonoperative management (NOM) failure.
Results: Of 1004 patients with BLSI, 128 patients were hypotensive in the Pediatric Trauma Center Emergency Department (ED); 65 total patients received vasopressors. Hypotension treated with vasopressors was associated with a sevenfold increase in mortality (AOR = 7.6 [p < 0.01]). When excluding patients first given vasopressors for cardiac arrest, the risk of mortality increased to 11-fold (AOR = 11.4 [p = 0.01]). All deaths in patients receiving vasopressors occurred when started within the first 12 h after injury. Vasopressor administration at any time was not associated with NOM failure.
Conclusion: After propensity matching, early vasopressor use for hypotension in the ED was associated with an increased risk of death, but did not increase the risk of failure of NOM.
Level of Evidence: Level III prognostic and epidemiological, prospective.
(Copyright © 2020 Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: